Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Bile Duct Cancer Market to Upsurge at a Significant CAGR by 2032, Assesses DelveInsight
March 23, 2023 06:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Bile Duct Cancer Market to Upsurge at a Significant CAGR by 2032, Assesses DelveInsight The bile duct cancer market is anticipated to surge in the...
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
May 28, 2021 08:51 ET
|
PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
PCI Biotech first quarter 2021 interim results
May 07, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation. ...
PCI Biotech to present at European Biotech Investor Days 2021
April 06, 2021 06:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 6 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that...
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
October 26, 2020 07:48 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech's fourth quarter and preliminary 2019 results
February 26, 2020 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...
Biliary Tumor Market to Gain Traction in the Coming Years; Advancements in NuCana’s Breakthrough Pipeline Drug Will Boost the Market, says Fortune Business Insights
June 19, 2019 07:45 ET
|
Fortune Business Insights
Pune, June 19, 2019 (GLOBE NEWSWIRE) -- The global Biliary Tumor Market is likely to derive growth from increasing usage approvals in the forthcoming years. According to an upcoming report by...
Delcath Announces Enrollment of First Patient in ALIGN Trial
October 18, 2018 08:00 ET
|
Delcath Systems, Inc.
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. ...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology
September 04, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems to Present at the 8th Annual LD Micro Invitational
May 29, 2018 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced...